Human DLL4 Active Recombinant Protein C-Fc Tag Lyophilized

Human DLL4 Recombinant Protein C-Fc Tag Lyophilized from Innovative Research has been recombinantly produced in HEK293 Cells. The protein formulation is lyophilized from sterile PBS; pH 7.4 with a purity of > 95 % as determined by reducing SDS-PAGE..

More Details:

• Species: Human
• Target: DLL4
• Purity: > 95 % as determined by reducing SDS-PAGE..< 1.0 EU per ug as determined by the LAL method.
• Source: HEK293 Cells
• Storage Conditions: Lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8? for 2-7 days. Aliquots of reconstituted samples are stable at < -20? for 3 months.

Delta-like protein 4 (DLL4; Delta4); a type I membrane-bound Notch ligand; is one of five known Notch ligands in mammals and interacts predominantly with Notch 1; which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth; forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore; the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions; such as cancer; DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis; but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies; blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density; yet causes marked growth inhibition due to functionally defective vasculature. Thus; DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy.

At Innovative Research, we provide reliable, consistent products that deliver reliable, consistent results.

For research use only.

View all citations and product references

This material is sold for in-vitro use only for research. This material is not suitable for human or animal use. While we make every effort to ensure the safety of our products, we recommend handling any biological materials with standard precautions as if capable of spreading infectious disease. The statements herein are offered for informational purposes only to be used solely for your consideration, investigation, and verification.

Please be aware the image pictured is for illustrative purposes only, and your product packaging and appearance may vary.